BACKGROUND/AIMS: To examine plasma levels of visfatin and endogenous secretory receptor for advanced glycation end-products (esRAGE) in diabetic and non-diabetic patients treated with intermittent hemodialysis (IHD), and to explore the possible associations between them, insulin resistance evaluated by homeostasis model assessment for insulin resistance (HOMA-IR), as well as selected biochemical and anthropometric parameters. METHODS: The study was carried out in 65 IHD patients. Type 2 diabetic patients (n = 28) were included into group I, non-diabetics (n = 37)-into group II. The reference group included 25 healthy volunteers. RESULTS: There were no significant differences between group I and II in plasma level of visfatin and esRAGE. HOMA-IR was higher in group I than in group II. In both groups these parameters were higher than in healthy subjects. In group I, visfatin correlated with insulin concentration (r = 0.428, P = 0.023), HOMA-IR with esRAGE (r = -0.374, P = 0.049). In group II, esRAGE correlated with waist-to-hip ratio (r = -0.343, P = 0.037), HOMA-IR with body mass index (r = 0.499, P = 0.001) and LDL cholesterol (r = -0.384, P = 0.018). CONCLUSIONS: Serum concentrations of visfatin and esRAGE are increased in IHD patients. There is no difference in visfatin and esRAGE levels between diabetic and non-diabetic IHD patients. In diabetic IHD patients receiving insulin, lower esRAGE levels are associated with higher insulin resistance, whereas plasma visfatin level is positively related to plasma insulin concentration. Waist-to-height ratio is a significant determinant of plasma visfatin level and HOMA-IR. Insulin resistance seems to be a link between esRAGE and visfatin in IHD diabetics.
BACKGROUND/AIMS: To examine plasma levels of visfatin and endogenous secretory receptor for advanced glycation end-products (esRAGE) in diabetic and non-diabeticpatients treated with intermittent hemodialysis (IHD), and to explore the possible associations between them, insulin resistance evaluated by homeostasis model assessment for insulin resistance (HOMA-IR), as well as selected biochemical and anthropometric parameters. METHODS: The study was carried out in 65 IHD patients. Type 2 diabeticpatients (n = 28) were included into group I, non-diabetics (n = 37)-into group II. The reference group included 25 healthy volunteers. RESULTS: There were no significant differences between group I and II in plasma level of visfatin and esRAGE. HOMA-IR was higher in group I than in group II. In both groups these parameters were higher than in healthy subjects. In group I, visfatin correlated with insulin concentration (r = 0.428, P = 0.023), HOMA-IR with esRAGE (r = -0.374, P = 0.049). In group II, esRAGE correlated with waist-to-hip ratio (r = -0.343, P = 0.037), HOMA-IR with body mass index (r = 0.499, P = 0.001) and LDL cholesterol (r = -0.384, P = 0.018). CONCLUSIONS: Serum concentrations of visfatin and esRAGE are increased in IHD patients. There is no difference in visfatin and esRAGE levels between diabetic and non-diabetic IHDpatients. In diabetic IHDpatients receiving insulin, lower esRAGE levels are associated with higher insulin resistance, whereas plasma visfatin level is positively related to plasma insulin concentration. Waist-to-height ratio is a significant determinant of plasma visfatin level and HOMA-IR. Insulin resistance seems to be a link between esRAGE and visfatin in IHD diabetics.
Authors: M Nishimura; M Murase; T Hashimoto; H Kobayashi; S Yamazaki; R Imai; K Okino; H Fujita; N Inoue; H Takahashi; T Ono Journal: Kidney Int Date: 2006-02 Impact factor: 10.612
Authors: A Bierhaus; S Schiekofer; M Schwaninger; M Andrassy; P M Humpert; J Chen; M Hong; T Luther; T Henle; I Klöting; M Morcos; M Hofmann; H Tritschler; B Weigle; M Kasper; M Smith; G Perry; A M Schmidt; D M Stern; H U Häring; E Schleicher; P P Nawroth Journal: Diabetes Date: 2001-12 Impact factor: 9.461
Authors: M Emoto; Y Nishizawa; K Maekawa; Y Hiura; H Kanda; T Kawagishi; T Shoji; Y Okuno; H Morii Journal: Diabetes Care Date: 1999-05 Impact factor: 19.112